Breaking newsCOVID-19Research
Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis
Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis
BioMed Alliance and 17 other civil society organisations call on policy makers to ensure that the next multiannual EU budget will be fit-for-purpose to address current and future health threats.
Latest Posts
-
-
Breaking newsCOVID-19Research
Incidence and impact of COVID-19 in MS. A survey from a Barcelona MS unit
Incidence and impact of COVID-19 in MS. A survey from a Barcelona MS unit -
Breaking newsCOVID-19Research
Presence of SARS-CoV-2 transcripts in the choroid plexus of MS and non-MS patients with COVID-19
Presence of SARS-CoV-2 transcripts in the choroid plexus of MS and non-MS patients with COVID-19 -
COVID-19 and the human innate immune system -
Breaking newsCOVID-19Research
Neurotropic effects of SARS-CoV-2 modeled by the human brain organoids
Neurotropic effects of SARS-CoV-2 modeled by the human brain organoids -
Breaking newsCOVID-19ResearchHuman neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection -
Breaking newsCOVID-19Research
Revealing tissue-specific SARS-CoV-2 infection and host responses using human stem cell derived lung and cerebral organoids
Revealing tissue-specific SARS-CoV-2 infection and host responses using human stem cell derived lung and cerebral organoids -
Breaking newsCOVID-19Research
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera -
The antigenic anatomy of SARS-CoV-2 receptor binding domain
-
Breaking newsCOVID-19Research
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera -
Breaking newsCOVID-19Research
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape -
Assessing the influence of climate on wintertime SARS-CoV-2 outbreaks
-
Breaking newsCOVID-19Research
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants -
Reduction in mobility and COVID-19 transmission
-
Breaking newsCOVID-19ResearchGlobal absence and targeting of protective immune states in severe COVID-19
Global absence and targeting of protective immune states in severe COVID-19